TABLE 4.
Mean and per cent change in Asthma Control Questionnaire (ACQ) and Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) outcome assessments at eight weeks
|
ICS
|
ICS/LABA
|
|||||||
|---|---|---|---|---|---|---|---|---|
| Low dose | Moderate dose | High dose | P* | Low dose | Moderate dose | High dose | P* | |
| Mean change in ACQ score | −1.18 (1.01) | −1.12 (0.94) | −1.28 (1.29) | 0.871 | −1.13 (1.02) | −1.01 (0.93) | −0.71 (0.87) | 0.459 |
| P value within group | <0.001 | <0.001 | 0.003 | <0.001 | <0.001 | 0.053 | ||
| Mean change in overall MiniRQLQ | −1.50 (1.39) | −1.33 (1.23) | −1.57 (1.60) | 0.750 | −1.50 (1.40) | −1.46 (1.29) | −0.98 (1.61) | 0.599 |
| P value within group | <0.001 | <0.001 | 0.003 | <0.001 | <0.001 | 0.128 | ||
| Mean change in MiniRQLQ domains | ||||||||
| Activities | −1.54 (1.52) | −1.43 (1.42) | −1.79 (1.41) | 0.716 | −1.66 (1.57) | −1.40 (1.58) | −0.96 (1.39) | 0.371 |
| P value within group | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.091 | ||
| Practical problems | −1.61 (1.74) | −1.59 (1.53) | −1.82 (2.03) | 0.898 | −1.78 (1.81) | −1.71 (1.72) | −0.75 (2.49) | 0.315 |
| P value within group | <0.001 | <0.001 | 0.005 | <0.001 | <0.001 | 0.423 | ||
| Nose symptoms | −1.81 (1.55) | −1.40 (1.37) | −1.43 (1.64) | 0.263 | −1.83 (1.67) | −1.57 (1.53) | −1.42 (1.94) | 0.598 |
| P value within group | <0.001 | <0.001 | 0.006 | <0.001 | <0.001 | 0.078 | ||
| Eye symptoms | −1.27 (1.72) | −1.19 (1.41) | −1.43 (1.95) | 0.882 | −1.07 (1.72) | −1.23 (1.58) | −1.17 (1.96) | 0.872 |
| P value within group | <0.001 | <0.001 | 0.017 | <0.001 | <0.001 | 0.136 | ||
| Other symptoms | −1.28 (1.39) | −1.31 (1.64) | −1.45 (1.85) | 0.922 | −1.53 (1.56) | −1.33 (1.58) | −0.54 (1.30) | 0.205 |
| P value within group | <0.001 | <0.001 | 0.012 | <0.001 | <0.001 | 0.276 | ||
| Per cent change in ACQ score | −55.6 (38.3) | −40.6 (98.4) | −44.0 (43.8) | 0.414 | −49.9 (44.1) | −50.6 (38.8) | −47.9 (51.6) | 0.987 |
| P value within group | <0.001 | 0.005 | 0.002 | <0.001 | <0.001 | 0.034 | ||
| Per cent change in overall MiniRQLQ | −49.6 (46.3) | −48.1 (47.3) | −53.5 (44.1) | 0.929 | −52.8 (44.4) | −51.5 (36.5) | −38.4 (60.6) | 0.664 |
| P value within group | <0.001 | <0.001 | 0.001 | <0.001 | <0.001 | 0.117 | ||
| Per cent change in MiniRQLQ domains | ||||||||
| Activities | −51.7 (47.9) | −50.8 (69.1) | −63.1 (39.0) | 0.750 | −55.9 (47.0) | −41.1 (69.8) | −44.9 (55.6) | 0.332 |
| P value within group | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.057 | ||
| Practical problems | −50.7 (45.0) | −41.3 (55.5) | −50.7 (48.8) | 0.549 | −39.5 (101.8) | −49.7 (43.7) | −15.8 (90.9) | 0.553 |
| P value within group | <0.001 | <0.001 | 0.002 | <0.001 | <0.001 | 0.637 | ||
| Nose symptoms | −56.3 (42.5) | −46.3 (46.1) | −47.4 (56.7) | 0.428 | −53.3 (46.6) | −45.1 (43.0) | −36.7 (62.0) | 0.445 |
| P value within group | <0.001 | <0.001 | 0.008 | <0.001 | <0.001 | 0.138 | ||
| Eye symptoms | −39.0 (64.4) | −42.1 (63.1) | −50.9 (48.7) | 0.809 | −28.3 (98.7) | −49.7 (44.4) | −35.0 (77.8) | 0.384 |
| P value within group | <0.001 | <0.001 | 0.003 | 0.009 | <0.001 | 0.244 | ||
| Other symptoms | −52.5 (45.3) | −40.4 (72.6) | −57.5 (47.4) | 0.421 | −54.5 (53.2) | −40.6 (70.6) | −27.1 (52.8) | 0.257 |
| P value within group | <0.001 | <0.001 | 0.001 | <0.001 | <0.001 | 0.190 | ||
*
Based on ANOVA. Within-group P value is based on the one-sample T-test. ICS Inhaled corticosteroid; LABA Long-acting beta-2-agonist.